Actively Recruiting
Evaluating Nemtabrutinib Combined with Pembrolizumab for Richter Transformation, Diffuse Large B-Cell Lymphoma
Led by Roswell Park Cancer Institute · Updated on 2026-10-02
32
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well nemtabrutinib combined with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype RT-DLBCL. This phase II trial aims to measure the overall response rate, safety, and quality of life in patients receiving this combination. The study also explores effects on immune cells, molecular subtypes of RT-DLBCL, and pharmacokinetics. Participants receive nemtabrutinib orally once daily on days 1 to 21 of each 21-day cycle and pembrolizumab intravenously on day 1 of each cycle. Treatment may continue for up to 35 cycles approximately 2 years unless the disease progresses or unacceptable side effects occur. Patients undergo various tests such as echocardiography or MUGA scans at screening, PETCT or CT scans, blood sample collections, and possibly bone marrow biopsies during the study. During the study, participants are regularly monitored through imaging and laboratory tests, questionnaires about quality of life, and safety assessments. After treatment ends, follow-up visits occur at 30 days and then every 6 months for up to 3 years or until death. The primary outcome measured is the overall response rate after 6 cycles about 18 weeks, with additional measures including survival, duration of response, and adverse events tracked for up to 3 years.
CONDITIONS
Brief Title
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here